{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Alzamend Neuro, Inc."},"Symbol":{"label":"Symbol","value":"ALZN"},"Address":{"label":"Address","value":"3500 LENOX ROAD NE SUITE 1500, ATLANTA, Georgia, 30326, United States"},"Phone":{"label":"Phone","value":"+1 844 722-6333"},"Industry":{"label":"Industry","value":" Medicinal Chemicals and Botanical Products "},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's."},"CompanyUrl":{"label":"Company Url","value":"https://www.alzamend.com"},"KeyExecutives":{"label":"Key Executives","value":[]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}